TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10488988
Drug: Ephedrine 0.12
Normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.12 mg
Study: 10488988
Drug: Ephedrine 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 0.24 mg
Study: 8945044
Drug: Model 1400T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 1400T lead (impregnated with steroid)
Study: 8945044
Drug: Model 1401T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 1401T lead (not impregnated with steroid)
Study: 27384580
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement (SUPP)
Study: 24782447
Drug: Vestibular suppressant
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular suppressant (dimenhydrinate 50 mg per day)
Study: 19114222
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (control, n=20)
Study: 14668570
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing with cilnidipine
Study: 14668570
Drug: Bedtime dosing
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dosing with cilnidipine
Study: 12482110
Drug: Pulsed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed estrogen therapy (Aerodiol®)
Study: 339940
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells
Study: 6944146
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy alone
Study: 23386704
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (4000 IU/day)
Study: 23386704
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (High-dose vitamin D and Placebo)
Study: 8066558
Drug: Auranofin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (3 mg orally twice a day)
Study: 3378222
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cis-diamminedichloroplatinum(II) at 30 mg/m2/day for 5 days
Study: 3378222
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cis-diamminedichloroplatinum(II)
Study: 27824882
Drug: HIV self-testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits and were encouraged to distribute one to their male partner or use both for testing as a couple.
Study: 27824882
Drug: HIV self-testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits.
Study: 11732148
Drug: mefloquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefloquine (10 mg/kg followed by 5 mg/kg at 6 h)
Study: 7963156
Drug: Prednisone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (single oral dose)
Study: 18344552
Drug: levobupivacaine 0.175%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.175% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 2)
Study: 18344552
Drug: levobupivacaine 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.15% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 1)
Study: 12390056
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg daily
Study: 9126664
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and 20 mg
Study: 23466100
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg and 40 mg
Study: 22578664
Drug: Humor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor therapy with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine two-hour sessions over 12 weeks.
Study: 22578664
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (control group) with no formal humor therapy.
Study: 16525815
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg potassium bromide daily for 20 weeks
Study: 16525815
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg potassium bromide daily for 20 weeks
Study: 12720588
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g ALNA/d
Study: 12720588
Drug: 0.44 g
Normalized name: MENTHOL 0.44 g in 100 g / ZINC OXIDE 21 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.44 g EPA+DHA/d
Study: 12720588
Drug: 0.94 g
Normalized name: BUPHENYL 0.94 GM/GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.94 g EPA+DHA/d
Study: 12720588
Drug: 1.9 g
Normalized name: aluminum phosphate 61.9 GM per 100 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9 g EPA+DHA/d
Study: 8322695
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg sublingually)
Study: 31869478
Drug: Child Life
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Life preparation (minimum 15 minutes)
Study: 25572038
Drug: Tryptophan-rich dietary
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan-rich dietary supplement from egg protein hydrolysate (0.5 g twice per day for 19 days)
Study: 25572038
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 g twice per day for 19 days)
Study: 20600734
Drug: Plain drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain drug tablets (FMT)
Study: 10857066
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (casting)
Study: 9165546
Drug: Standard fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fixed dose of 500 mg/day of oral zidovudine
Study: 9165546
Drug: Concentration-controlled regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled regimen of oral zidovudine
Study: 1587194
Drug: Ranitidine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (mean 2150 mg/day, range 1200-3000 mg/day)
Study: 1587194
Drug: Omeprazole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (mean 33 mg/day, range 20-60 mg/day)
Study: 2422479
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg sulphinpyrazone (SP)
Study: 2422479
Drug: 880 mg
Normalized name: calcium carbonate 1880 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 880 mg acetylsalicylic acid (ASA)
Study: 30833170
Drug: Semaglutide 1·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1·0 mg
Study: 31540617
Drug: Integrated Stepped
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Integrated Stepped Alcohol Treatment (ISAT)
Study: 21955862
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (100 mg/day losartan after 40 mg/d enalapril for 4 months)
Study: 14744276
Drug: High-dose eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose eptifibatide (two 180-microg/kg single-dose boluses before CAS, then a 2.0-microg/kg/min infusion for 20-24 hours)
Study: 27520989
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (control group)
Study: 8417172
Drug: Ribavirin 600
Normalized name: ribavirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 600 mg or 800 mg for 24 weeks
Study: 28923084
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy alone
Study: 31870421
Drug: Tailored psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored psychological intervention (access to psychological treatment)
Study: 19141765
Drug: Standard DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DHA in infants born weighing less than 1250 g
Study: 19141765
Drug: High-DHA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-DHA diet in infants born weighing at least 1250 g
Study: 19141765
Drug: Standard DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DHA in infants born weighing at least 1250 g
Study: 2968769
Drug: Salbutamol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.3 mg (SAL)
Study: 2968769
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Salbutamol 0.3 mg and Disodium Cromoglycate 3 mg (SAL + DSCG)
Study: 2968769
Drug: Disodium Cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium Cromoglycate 3 mg (DSCG)
Study: 12830444
Drug: Daily HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily HD
Study: 15328635
Drug: Intraoperative application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative application of 50 mg 5‐FU (Group A)
Study: 15328635
Drug: Postoperative subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subconjunctival injections of 5 mg 5‐FU (Group B)
Study: 15328635
Drug: Intra and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra and postoperative administration of 5‐FU (Group C)
Study: 29781394
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy with Relaxation (CBT + R)
Study: 28549015
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (EOF) on the first postoperative day
Study: 28549015
Drug: Late oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late oral feeding (LOF) 7 days after surgery
Study: 28549015
Drug: Late oral
Normalized name: Adalate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late oral feeding (LOF)
Study: 25997842
Drug: Self-distancing (exemplar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-distancing (exemplar perspective, e.g., Batman)
Study: 15664716
Drug: 15 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/70 kg d-amphetamine
Study: 15664716
Drug: 7.5 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/70 kg d-amphetamine
Study: 15664716
Drug: 0 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/70 kg (placebo)
Study: 7976644
Drug: Morphine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (mean rate 2.3 mg/h, range 0‐4 mg/h)
Study: 7976644
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean rate 2.8 mg/h, range 0‐5 mg/h)
Study: 1095246
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate aerosol (400 mug/day)
Study: 28051240
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy using azithromycin and bronchodilators or glucocorticoid
Study: 15837236
Drug: ACAM2000 (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAM2000 (highest dose)
Study: 12888057
Drug: Control eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eyes (conventional LASIK treatment)
Study: 10454950
Drug: Sulfonylureas, Metformin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas, Metformin, or Insulin
Study: 6350090
Drug: Propafenone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (900 mg/day)
Study: 17882923
Drug: Mometasone nasal
Normalized name: mometasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone nasal spray
Study: 16280286
Drug: Irbesartan/HCTZ (150/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ (150/12.5 mg)
Study: 16280286
Drug: Valsartan/HCTZ (80/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ (80/12.5 mg)
Study: 28407625
Drug: Mapracorat 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapracorat 0.1% ointment
Study: 8929242
Drug: Reference drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drugs
Study: 19780001
Drug: Botulinum toxin‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin‐A injection (25 U, 0.5 ml, once)
Study: 19780001
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection (2 ml, 20 mg, 1% lidocaine, twice a week for one month)
Study: 19780001
Drug: Laser treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatments (20 sessions)
Study: 11565402
Drug: Magnet-on group
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnet-on group (active treatment)
Study: 31825248
Drug: SAR341402 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR341402 insulin aspart
Study: 31223099
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion (1 h) of Zn (100 μmol)
Study: 31223099
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (10 h) of Se (1 μmol)
Study: 31223099
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion (1 h) of Cr (200 nmol)
Study: 31223099
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (10 h) of Cr (200 nmol)
Study: 31223099
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion (1 h) of Cu (8 μmol)
Study: 31223099
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (10 h) of Cu (8 μmol)
Study: 31223099
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion (1 h) of Fe (20 μmol)
Study: 31223099
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion (10 h) of Fe (20 μmol)
Study: 31725351
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Study: 25100336
Drug: 80 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp, 2.2 pitch, 20 ml of contrast medium and sinogram affirmed iterative reconstruction
Study: 9113175
Drug: bupivacaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 12.5 mg + 10 micrograms fentanyl subarachnoidally
Study: 9113175
Drug: bupivacaine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 12.5 mg + saline subarachnoidally
Study: 9113175
Drug: bupivacaine 100
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 100 mg + saline epidurally
Study: 3301785
Drug: Colistin inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin inhalation (1 million units twice daily for three months)
Study: 3301785
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (isotonic saline)
Study: 3301785
Drug: Colistin inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin inhalation
Study: 8626983
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation
Study: 30984320
Drug: Occlusal appliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal appliance (OA) with nonsteroidal anti‐inflammatory drug (NSAID) therapy (nimesulide)
Study: 29136001
Drug: Combination Intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Intervention Strategy (CIS)
Study: 18077134
Drug: 15 mg/d
Normalized name: Valtoco, 15 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/d of supplemental Zn
Study: 18424598
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of pureed strawberries (15 micromol anthocyanin)
Study: 18424598
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g of pureed strawberries (30 micromol anthocyanin)
Study: 22839504
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline injection)
Study: 11830801
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine
Study: 3902184
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 100 mg twice a day
Study: 3045113
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg)
Study: 15209786
Drug: Flashlamp-pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flashlamp-pulsed dye laser treatment
Study: 3132866
Drug: Flumazenil (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.8 mg/70 kg)
Study: 30668352
Drug: Mastiha (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastiha (2.8 g/day)
Study: 28586537
Drug: Vericiguat 10
Normalized name: vericiguat 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 10 mg once daily
Study: 19509121
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of bisphosphonate treatment
Study: 19509121
Drug: 10 years
Normalized name: Neocate Junior Powder Children 1-10 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 years of bisphosphonate treatment
Study: 9207310
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2 intravenously once a week for 3 weeks (days 1, 8, and 15) followed by a 1-week rest period.
Study: 9207310
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 intravenously on day 1 of each 28-day cycle in combination with etoposide 100 mg/m2 on days 1, 2, and 3.
Study: 6832198
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg/kg i.v.)
Study: 25344881
Drug: SCPB (Superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCPB (Superficial Cervical Plexus Block) with 10 ml 0.25% bupivacaine each side
Study: 26404199
Drug: Ticagrelor 270
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 270 mg loading dose
Study: 29023473
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose
Study: 26404199
Drug: Ticagrelor 360
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 360 mg loading dose
Study: 26404199
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg, 270 mg, 360 mg loading doses
Study: 29696963
Drug: Aspirin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (control group)
Study: 10223211
Drug: Permethrin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin (200 mg/m2)
Study: 10223211
Drug: Lambdacyhalothrin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lambdacyhalothrin (3 mg/m2)
Study: 10223211
Drug: Lambdacyhalothrin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lambdacyhalothrin (15 mg/m2)
Study: 8272303
Drug: Higher-dose monophasic
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose monophasic pill
Study: 8272303
Drug: Lower-dose monophasic
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose monophasic pill
Study: 7705531
Drug: Multiphasic pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphasic pill
Study: 2679084
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 to 20 mg once every afternoon (stratum II)
Study: 2679084
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily (both strata)
Study: 2679084
Drug: Simvastatin 5
Normalized name: simvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5 to 10 mg once every afternoon (stratum I)
Study: 2679084
Drug: Simvastatin 5
Normalized name: simvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5 to 10 mg once every afternoon and gemfibrozil 600 mg twice daily
Study: 2679084
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 to 20 mg once every afternoon
Study: 17029618
Drug: 40 tablets
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 tablets (60 g) of NaP
Study: 17029618
Drug: RF-NaP 40
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RF-NaP 40 tablets (60 g)
Study: 12767425
Drug: L-thyroxine (L-T(4))
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (L-T(4)) replacement therapy for 6 months
Study: 12767425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of 14 euthyroid patients (52.5 +/- 10 years); thyroid-stimulating hormone 2.5 +/- 1.2 microUI/ml
Study: 4604478
Drug: Whole-cell Inaba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell Inaba vaccine (2 annual injections)
Study: 29240757
Drug: 10 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 session integrated cognitive behavioral therapy and HIV prevention intervention (n = 162)
Study: 19221370
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (80 mg bolus followed by 8 mg/h infusion for 72 hours)